Latest VivoSim Labs News & Updates

See the latest news and media coverage for VivoSim. We track all announcements, press releases, and industry mentions in real time, all in one place.

VivoSim Labs (VivoSim)

Human-relevant 3D liver and intestinal toxicology platform

vivosim.ai

Headquarters: San Diego, United States
Founded year: 2007
Company type: Public company
Number of employees: 30–50
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about VivoSim Labs (VivoSim)

In short: VivoSim received a $5M Eli Lilly milestone, forecast 500%+ revenue growth, and showcased high-accuracy NAMkind toxicity data.

Company announcements

August 17 VivoSim

VivoSim receives Nasdaq delisting warning

The company must restore its minimum bid price by February 2027 or consider a reverse stock split.

August 10 VivoSim

VivoSim reports Q1 2026 financial results with reduced net loss

The company generated $18k in royalty revenue and incurred a net loss of $1.3 million, driven by R&D and SG&A expenses totaling nearly $2.8 million.

August 10 VivoSim

VivoSim Labs files PRE 14A proxy statement

The preliminary proxy statement is dated September 30, 2026 and was filed with the SEC on August 10, 2026.

August 6 VivoSim

VivoSim regains Nasdaq compliance and updates financials

Received $5 million milestone and $1 million escrow release from Eli Lilly, completed $4 million financing, and holds $10.1 million cash.

Media coverage

October 7 Yahoo Finance

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costsSAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE...

September 28 FinancialContent

VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs

The platform's commercial potential is highlighted by VivoSim's relationship with Eli Lilly and Company ( NYSE: LLY). VivoSim received a $5 million milestone payment related...

September 14 FinancialContent

Catch the Danger, Spare the Cure: Why VivoSim's (NASDAQ: VIVS) 90%/95% Toxicity Results Matter

VivoSim has reported that its NAMkind™ Liver platform achieved approximately 91% overall predictive accuracy, 90% sensitivity and 95% specificity against clinical drug-induced liver injury outcomes...

August 12 Houston Chronicle

VivoSim: Fiscal Q1 Earnings Snapshot

SAN DIEGO (AP) — SAN DIEGO (AP) — VivoSim Labs, Inc. (VIVS) on Wednesday reported a loss of $1.3 million in its fiscal first quarter...

Never miss news about VivoSim

Track VivoSim and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.